Ultragenyx Pharmaceutical Faces Class Action Lawsuit After Study Results Fail to Meet Expectations
On March 17, 2026, The Gross Law Firm issued an urgent alert for shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), advising them of a class action lawsuit stemming from substantial losses in share value. Those who purchased shares during the class period from August 3, 2023, to December 26, 2025, are encouraged to seek further information. The allegations state that Ultragenyx executives made overly optimistic claims while downplaying crucial risk factors related to the company's clinical studies, specifically focusing on their treatment, setrusumab.
The contentious clinical trials, named Orbit and Cosmic, were intended to validate the efficacy of setrusumab in reducing fracture rates among patients. However, the company's December 29, 2025 announcement revealed that these studies failed to achieve statistically significant outcomes. The public learned that the supposed increase in bone density did not correlate with decreased fracture rates, which contradicts what Ultragenyx leadership had communicated to the investment community.
This disappointing news triggered a dramatic stock price drop for Ultragenyx, plummeting nearly 42% in just one day. Stocks fell from $34.19 per share on December 26, 2025, to just $19.72 per share two days later, raising urgent concerns amongst investors who felt misled.
Shareholders of Ultragenyx are urged to take immediate action and register for inclusion in this class action by April 6, 2026. Registering does not mandate involvement as a lead plaintiff, yet it unlocks access to updates and information through a portfolio monitoring service related to the case's progression.
The Gross Law Firm, which is a nationally recognized class action law firm, emphasizes its commitment to protecting investor rights in instances of corporate misconduct and misrepresentation. They explain that investors are often affected by misleading information that inflates stock prices artificially, leading to substantial financial repercussions once the truth emerges.
It is vital for shareholders to consider their options seriously and to get involved in seeking recourse against Ultragenyx for the losses they may have incurred due to the alleged misleading statements.
For more information, investors can reach out to The Gross Law Firm directly at their New York office. As this case unfolds, shareholders can stay updated through various communications facilitated by the law firm. With the mentioned deadline approaching, it is crucial for affected investors to act swiftly in potentially reclaiming their losses.
The contentious clinical trials, named Orbit and Cosmic, were intended to validate the efficacy of setrusumab in reducing fracture rates among patients. However, the company's December 29, 2025 announcement revealed that these studies failed to achieve statistically significant outcomes. The public learned that the supposed increase in bone density did not correlate with decreased fracture rates, which contradicts what Ultragenyx leadership had communicated to the investment community.
This disappointing news triggered a dramatic stock price drop for Ultragenyx, plummeting nearly 42% in just one day. Stocks fell from $34.19 per share on December 26, 2025, to just $19.72 per share two days later, raising urgent concerns amongst investors who felt misled.
Shareholders of Ultragenyx are urged to take immediate action and register for inclusion in this class action by April 6, 2026. Registering does not mandate involvement as a lead plaintiff, yet it unlocks access to updates and information through a portfolio monitoring service related to the case's progression.
The Gross Law Firm, which is a nationally recognized class action law firm, emphasizes its commitment to protecting investor rights in instances of corporate misconduct and misrepresentation. They explain that investors are often affected by misleading information that inflates stock prices artificially, leading to substantial financial repercussions once the truth emerges.
It is vital for shareholders to consider their options seriously and to get involved in seeking recourse against Ultragenyx for the losses they may have incurred due to the alleged misleading statements.
For more information, investors can reach out to The Gross Law Firm directly at their New York office. As this case unfolds, shareholders can stay updated through various communications facilitated by the law firm. With the mentioned deadline approaching, it is crucial for affected investors to act swiftly in potentially reclaiming their losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.